59 related articles for article (PubMed ID: 35917132)
41. Myositis Specific Autoantibodies: A Clinical Perspective.
Alenzi FM
Open Access Rheumatol; 2020; 12():9-14. PubMed ID: 32021502
[TBL] [Abstract][Full Text] [Related]
42. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.
Betteridge Z; McHugh N
J Intern Med; 2016 Jul; 280(1):8-23. PubMed ID: 26602539
[TBL] [Abstract][Full Text] [Related]
43. [Myositis-specific autoantibodies].
Fujimoto M
Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
[TBL] [Abstract][Full Text] [Related]
44. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
45. Dermatomyositis: Practical Guidance and Unmet Needs.
Cassard L; Seraly N; Riegert M; Patel A; Fernandez AP
Immunotargets Ther; 2024; 13():151-172. PubMed ID: 38464459
[TBL] [Abstract][Full Text] [Related]
46. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis.
Marzęcka M; Niemczyk A; Rudnicka L
Clin Rev Allergy Immunol; 2022 Oct; 63(2):289-296. PubMed ID: 35147864
[TBL] [Abstract][Full Text] [Related]
47. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Demortier J; Vautier M; Chosidow O; Gallay L; Bessis D; Berezne A; Cordel N; Schmidt J; Smail A; Duffau P; Jachiet M; Begon E; Gottlieb J; Chasset F; Graveleau J; Marque M; Cesbron E; Forestier A; Josse S; Kluger N; Beauchêne C; Le Corre Y; Pagis V; Rigolet A; Guillaume-Jugnot P; Authier FJ; Guilain N; Streichenberger N; Leonard-Louis S; Boussouar S; Landon-Cardinal O; Benveniste O; Allenbach Y
Rheumatology (Oxford); 2023 Dec; 62(12):3932-3939. PubMed ID: 37010495
[TBL] [Abstract][Full Text] [Related]
48. Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for clinicians.
Mehta P; Aggarwal R; Porter JC; Gunawardena H
Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101769. PubMed ID: 35840503
[TBL] [Abstract][Full Text] [Related]
49. Update on dermatomyositis.
Tanboon J; Nishino I
Curr Opin Neurol; 2022 Oct; 35(5):611-621. PubMed ID: 35942671
[TBL] [Abstract][Full Text] [Related]
50. A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.
Sevim E; Kobrin D; Casal-Dominguez M; Pinal-Fernandez I
Expert Rev Clin Immunol; 2024 Feb; 20(2):197-209. PubMed ID: 37842905
[TBL] [Abstract][Full Text] [Related]
51. Current concepts and advances in dermatomyositis: a dermatological perspective.
Lim D; Fiorentino D; Werth V
Clin Exp Rheumatol; 2023 Mar; 41(2):359-369. PubMed ID: 36622138
[TBL] [Abstract][Full Text] [Related]
52. COVID-19 Disease and Dermatomyositis: A Mini-Review.
Qian J; Xu H
Front Immunol; 2021; 12():747116. PubMed ID: 35095837
[TBL] [Abstract][Full Text] [Related]
53. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review.
Yu K; Wang T; An D; Li X; Tang Z
Semin Arthritis Rheum; 2024 Aug; 67():152478. PubMed ID: 38833729
[TBL] [Abstract][Full Text] [Related]
54. Novel therapeutic targets in dermatomyositis.
Bax C; Aghdasi C; Fiorentino D
J Dermatol; 2024 Mar; ():. PubMed ID: 38433369
[TBL] [Abstract][Full Text] [Related]
55. The associations between myositis autoantibodies and clinical presentations in dermatomyositis.
Su HJ; Chung WH; Lin CY
Australas J Dermatol; 2022 Nov; 63(4):479-487. PubMed ID: 35917132
[TBL] [Abstract][Full Text] [Related]
56. Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies.
Okiyama N; Fujimoto M
F1000Res; 2019; 8():. PubMed ID: 31824645
[TBL] [Abstract][Full Text] [Related]
57. Management of Myositis-Associated Interstitial Lung Disease.
Fujisawa T
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
[TBL] [Abstract][Full Text] [Related]
58. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
[TBL] [Abstract][Full Text] [Related]
59. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review.
Kilinc OC; Ugurlu S
Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
